Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DEGS1 | O15121 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | PRKDC | P78527 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | ATR | Q13535 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | GLS | O94925 | 1/20 | 0.42 |
| ▸ | WNT3A | P56704 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1354289 | 0.99 | DEGS1 (0.50) | DEGS1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL12839941 | 0.98 | DEGS1 (0.49) | DEGS1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL12838880 | 0.95 | KMT2A (0.46) | DEGS1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL12838882 | 0.95 | DEGS1 (0.45) | DEGS1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL12838890 | 0.95 | DEGS1 (0.45) | DEGS1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL12838494 | 0.95 | KMT2A (0.46) | DEGS1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL12838881 | 0.95 | DEGS1 (0.45) | DEGS1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL12839658 | 0.95 | DEGS1 (0.45) | DEGS1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL15343487 | 0.93 | MCL1 (0.43) | DEGS1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL15343485 | 0.92 | APP (0.51) | MEN1KMT2ANPC1RAB9AMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 973 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10156557-B2 | Calcium-binding photoprotein | JNC CORPORATION (JP) | 2018-12-18 | — | — | US | claimed |
| US-9678067-B2 | Method for extending light-emitting time of calcium-binding photoprotein solution | JNC CORPORATION (JP) | 2017-06-13 | — | — | US | claimed |
| US-20140329250-A1 | CALCIUM-BINDING PHOTOPROTEIN | JNC CORP (JP) | 2014-11-06 | — | — | US | claimed |
| US-8816052-B2 | Mutant apoprotein of photoprotein with low calcium sensitivity | JNC CORPORATION (JP) | 2014-08-26 | — | — | US | claimed |
| US-8710195-B2 | Fluorescent proteins | JNC CORPORATION (JP) | 2014-04-29 | — | — | US | claimed |
| US-20120258465-A1 | MUTANT APOPROTEIN OF PHOTOPROTEIN WITH LOW CALCIUM SENSITIVITY | JNC CORPORATION (JP) | 2012-10-11 | — | — | US | claimed |
| US-20110070656-A1 | Fluorescent Proteins | JNC CORPORATION (JP) | 2011-03-24 | — | — | US | claimed |
| US-20100311051-A1 | Calcium-binding photoprotein, gene encoding the same and use thereof | CHISSO CORPORATION | 2010-12-09 | — | — | US | claimed |
| EP-1666488-B1 | FLUORESCENT PROTEIN | CHISSO CORP (JP) | 2010-11-17 | — | — | EP | claimed |
| US-7396655-B2 | Method for enhancing activity of luciferase with fluorescence activity | CHISSO CORPORATION (JP) | 2008-07-08 | — | — | US | claimed |
| US-20060234324-A1 | Method for enhancing activity of luciferase with fluorescence activity | CHISSO CORPORATION (JP) | 2006-10-19 | — | — | US | claimed |
| US-20060044781-A1 | Bioluminescent fog for military and law enforcement | ADVANCED ENERGY INDUSTRIES, INC. | 2006-03-02 | — | — | US | claimed |
| US-12630492-B2 | Cannabinoid derivatives | CANOPY GROWTH CORPORATION (CA) | 2026-05-19 | — | — | US | disclosed |
| EP-4731219-A2 | COMPOUNDS AND METHODS OF USE THEREOF FOR ASSESSING TARGET ENGAGEMENT FOR DNA POLYMERASE THETA | Promega Corporation (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12596119-B2 | Analyte detection immunoassay | PROMEGA CORPORATION (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260028662-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | PROMEGA CORP (US) | 2026-01-29 | — | — | US | disclosed |
| WO-1997029319-A2 | BIOLUMINESCENT NOVELTY ITEMS | BRYAN BRUCE J (US) | 1997-08-14 | — | — | WO | disclosed |
| EP-0721509-A1 | FERTILE, TRANSGENIC MAIZE PLANTS AND METHODS FOR THEIR PRODUCTION | DeKalb Genetics Corporation (US) | 1996-07-17 | — | — | EP | disclosed |
| WO-1995006128-A9 | FERTILE, TRANSGENIC MAIZE PLANTS AND METHODS FOR THEIR PRODUCTION | — | 1995-03-30 | — | — | WO | disclosed |
| WO-1995006128-A2 | FERTILE, TRANSGENIC MAIZE PLANTS AND METHODS FOR THEIR PRODUCTION | DEKALB GENETICS CORPORATION (US) | 1995-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630492-B2 | Cannabinoid derivatives | CNR2, CNR1, OPRM1 | DEGS1 226/4885MEN1 2519/4885KMT2A 210/4885 |
| US-20060234324-A1 | Method for enhancing activity of luciferase with fluorescence activity | CACYBP, PRCP, GBA3 | DEGS1 4828/4885MEN1 3437/4885KMT2A 2996/4885 |
| US-12596119-B2 | Analyte detection immunoassay | FEM1B, CTNNBL1, GSKIP | DEGS1 4863/4885MEN1 3331/4885KMT2A 3267/4885 |
| US-20140329250-A1 | CALCIUM-BINDING PHOTOPROTEIN | CACYBP, ORAI2, ITPR2 | DEGS1 3991/4885MEN1 4162/4885KMT2A 2998/4885 |
| US-20260028662-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | RNGTT, VIP, PREP | DEGS1 3672/4885MEN1 3446/4885KMT2A 3368/4885 |
| US-10156557-B2 | Calcium-binding photoprotein | CACYBP, ORAI2, ITPR2 | DEGS1 3991/4885MEN1 4162/4885KMT2A 2998/4885 |
| US-20110070656-A1 | Fluorescent Proteins | CACYBP, CHLSN, LCP2 | DEGS1 4476/4885MEN1 3926/4885KMT2A 4653/4885 |
| US-20100311051-A1 | Calcium-binding photoprotein, gene encoding the same and use thereof | CACYBP, ORAI2, CIB1 | DEGS1 4277/4885MEN1 4069/4885KMT2A 3236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.